Synapse - Matthew Hellmann

Results (412)

Identification of gene signatures associated with response in a phase II trial of entinostat (ENT) plus pembrolizumab (PEMBRO) in non-small cell lung cancer (NSCLC) patients whose disease has progressed on or after anti-PD-(L)1 therapy

Meeting Abstract

Ordentlich, P.; Wang, L.; Tamang, D.; Sullivan, A. H.; Church, S. E.; Rozelle, D.; Meyers, M. L.; Ramalingam, S. S.; Hellmann, M. D.
Cancer Research (2019)

Fulltext@MSK | Save

Inherited truncating RAD52 variant discovered using integrated germline-somatic analysis predicts clinical outcome in patients with lung cancers

Meeting Abstract

Mukherjee, S.; Srinivasan, P.; Bandlamudi, C.; Hellmann, M. D.; Ravichandran, V.; Selvan, M. E.; Kemel, Y.; Mandelker, D.; Zauderer, M.; Walsh, M.; more...
Cancer Research (2019)

Fulltext@MSK | Save

KEYNOTE-495/KeyImPaCT: Phase II biomarker-directed precision oncology study of pembrolizumab-based combination therapy for non-small cell lung cancer

Meeting Abstract

Gutierrez, M.; Hellmann, M. D.; Gubens, M.; Aggarwal, C.; Tan, D. S. W.; Felip, E.; Chiu, J. W. Y.; Lee, J. S.; Yang, J. C. H.; Garon, E.; more...
Cancer Research (2019)

Fulltext@MSK | Save

Inter-test variability in tumor mutational burden (TMB) quantification and identification of TMB thresholds

Meeting Abstract

Vokes, N.; Alguilar, E. J.; Umeton, R.; Adeni, A.; Sholl, L.; Hellmann, M.; Rizvi, H.; Awad, M.; Van Allen, E.
Cancer Research (2019)

Fulltext@MSK | Save

Coupling neoantigen specific T cell clonotypes and their molecular phenotypes at the single cell level in resectable anti-PD-1 treated NSCLC

Meeting Abstract

Caushi, J. X.; Ji, Z.; Zhang, J.; El Asmar, M.; Anagnostou, V.; Cottrell, T. R.; Chan, H. Y.; Guo, H.; Merghoub, T.; Wolchok, J. D.; more...
Cancer Research (2019)

Fulltext@MSK | Save

Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: Results from the phase I KEYNOTE-001 study